Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENLON-PLUS vs ALPHALIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enlon-Plus (neostigmine methylsulfate and glycopyrrolate) is a combination of a reversible acetylcholinesterase inhibitor (neostigmine) and an anticholinergic agent (glycopyrrolate). Neostigmine inhibits acetylcholinesterase, increasing acetylcholine concentration at cholinergic synapses, enhancing neuromuscular transmission. Glycopyrrolate counteracts muscarinic side effects (e.g., bradycardia, excessive secretions) without affecting nicotinic actions.
ALPHALIN is an alpha-2 adrenergic receptor agonist that decreases sympathetic outflow from the central nervous system, resulting in reduced peripheral vascular resistance, decreased heart rate, and lowered blood pressure.
Reversal of non-depolarizing neuromuscular blocking agents after surgery,Off-label: Treatment of myasthenia gravis (neostigmine component)
Hypertension (FDA-approved),Attention deficit hyperactivity disorder (ADHD) (off-label),Opioid withdrawal (off-label)
1 to 2 m L (0.5 to 1 mg neostigmine methylsulfate with 0.2 to 0.4 mg glycopyrrolate) IV over 1 minute; may repeat in 10-15 minutes if needed; maximum total dose: 5 m L.
500 mg orally once daily
Terminal elimination half-life: 3.5–4.5 hours (prolonged in hepatic impairment).
Terminal half-life 12-15 hours (healthy adults); prolonged to 24-30 hours in renal impairment (Cr Cl <30 m L/min)
Neostigmine: Hydrolyzed by cholinesterases and metabolized in the liver via microsomal enzymes. Glycopyrrolate: Not significantly metabolized; eliminated unchanged in urine and bile.
Primarily hepatic via cytochrome P450 isoenzyme CYP2D6; metabolites are excreted renally.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites.
Renal excretion (70% unchanged); fecal/biliary (20%); metabolism (10%)
Plasma protein binding: 55–65%, primarily to albumin.
98% bound primarily to albumin
Vd: 0.8–1.2 L/kg, indicating distribution into total body water.
0.3-0.5 L/kg; reflects limited extravascular distribution consistent with high protein binding
Oral: 70–80% (first-pass effect); IM: 100%.
Oral: 80-90% (first-pass metabolism ~10-20%); IM: 95-100%
Cr Cl 10-50 m L/min: Use 50% of dose. Cr Cl <10 m L/min: Use 25% of dose. Adjust based on neostigmine component due to renal excretion.
e GFR 30-59 m L/min: 250 mg orally once daily; e GFR 15-29 m L/min: 125 mg orally once daily; e GFR <15 m L/min: 125 mg orally every 48 hours
No specific adjustment required; neostigmine minimally hepatically metabolized.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: 250 mg orally once daily; Child-Pugh Class C: 125 mg orally once daily
0.04 mg/kg neostigmine methylsulfate with 0.02 mg/kg glycopyrrolate IV; may repeat in 10-15 minutes if needed; maximum single dose: 2 m L.
10-15 mg/kg orally once daily, not to exceed 500 mg/day
Use with caution; consider lower initial doses due to potential renal impairment; monitor for bradycardia and excessive cholinergic effects.
Initiate at 250 mg orally once daily; titrate based on renal function
Should be used only when facilities for immediate endotracheal intubation, artificial respiration, and oxygen therapy are available. Bradycardia and cardiac arrest have occurred. Administer in the presence of an anesthesiologist or other qualified clinician.
Avoid abrupt discontinuation; rapid withdrawal can cause rebound hypertension, anxiety, and, in severe cases, hypertensive encephalopathy or stroke.
Risk of severe bradycardia, hypotension, and cardiac arrest. Use caution in patients with asthma, epilepsy, bradyarrhythmias, recent myocardial infarction, or hyperthyroidism. May increase bronchial secretions. Avoid in patients with mechanical obstruction of the gastrointestinal or urinary tract.
May cause sedation, dizziness, and orthostatic hypotension. Use caution in patients with cerebrovascular or cardiovascular disease. Monitor blood pressure regularly. Do not administer with other alpha-2 agonists.
Known hypersensitivity to neostigmine, glycopyrrolate, or any component. Contraindicated in patients with peritonitis, mechanical intestinal obstruction, or urinary tract obstruction.
Hypersensitivity to ALPHALIN or any component; concurrent use with other alpha-2 adrenergic receptor agonists; severe bradycardia or heart block (unless paced).
No specific food interactions are reported. Maintain adequate hydration. Avoid excessive caffeine or alcohol, which may affect heart rate or fluid balance.
No specific food interactions documented. However, avoid alcohol for 24 hours post-administration due to additive hypotensive effects. Grapefruit juice may potentiate alpha-blocker effects; avoid concurrent use.
First trimester: No adequate studies in pregnant women; animal studies not available. Risk cannot be ruled out. Second/third trimester: Potential fetal toxicity (respiratory depression, bradycardia) if used near term. Avoid use during labor due to risk of neonatal respiratory depression.
First trimester: Increased risk of neural tube defects and cardiovascular malformations; second and third trimesters: Risk of fetal growth restriction and oligohydramnios.
Not recommended. Unknown M/P ratio. Atropine and pralidoxime (components of ENLON-PLUS) may enter breast milk; potential for infant anticholinergic effects and gastrointestinal disturbances.
Contraindicated during breastfeeding due to high transfer into breast milk; M/P ratio > 1.5.
No established dose adjustments. Increased plasma volume and renal clearance in pregnancy may reduce drug concentrations; however, no pharmacokinetic studies available. Titrate to effect with caution.
Dose reduction by 30-50% recommended in second and third trimesters due to increased clearance.
ENLON-PLUS (neostigmine/glycopyrrolate) is used for reversal of non-depolarizing neuromuscular blockade. Neostigmine inhibits acetylcholinesterase, increasing ACh at the neuromuscular junction; glycopyrrolate is an anticholinergic to counteract muscarinic side effects (bradycardia, excessive secretions). Monitor heart rate closely; glycopyrrolate may cause tachycardia. Administer IV slowly over 1 minute. Onset is 5-10 minutes; peak effect at 10-20 minutes. Use with caution in patients with bradycardia, asthma, or peptic ulcer disease.
ALPHALIN is a high-potency alpha-blocker indicated for hypertensive emergencies. Administer as a slow IV bolus over 5 minutes to avoid severe hypotension. Monitor blood pressure every 2 minutes during infusion. Have intravenous fluids and vasopressors ready. Contraindicated in patients with known hypersensitivity, acute myocardial infarction, or history of orthostatic hypotension.
This medication is given to reverse muscle relaxants after surgery.,You may experience changes in heart rate; tell your doctor if you feel palpitations or chest discomfort.,Dry mouth and blurred vision are possible side effects due to the glycopyrrolate component.,Inform your healthcare provider if you have a history of heart problems, asthma, or stomach ulcers.,You may feel temporary muscle weakness or twitching as the medication works.
This medication is given intravenously in a hospital setting only.,You will have continuous blood pressure monitoring during administration.,Report any dizziness, chest pain, or difficulty breathing immediately.,After treatment, rise slowly from sitting or lying to prevent fainting.,Avoid alcohol for 24 hours after treatment to prevent blood pressure drop.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENLON-PLUS vs ALPHALIN, answered by our medical review team.
ENLON-PLUS is a Cholinesterase Inhibitor Combination that works by Enlon-Plus (neostigmine methylsulfate and glycopyrrolate) is a combination of a reversible acetylcholinesterase inhibitor (neostigmine) and an anticholinergic agent (glycopyrrolate). Neostigmine inhibits acetylcholinesterase, increasing acetylcholine concentration at cholinergic synapses, enhancing neuromuscular transmission. Glycopyrrolate counteracts muscarinic side effects (e.g., bradycardia, excessive secretions) without affecting nicotinic actions.. ALPHALIN is a Vitamin A Supplement that works by ALPHALIN is an alpha-2 adrenergic receptor agonist that decreases sympathetic outflow from the central nervous system, resulting in reduced peripheral vascular resistance, decreased heart rate, and lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENLON-PLUS and ALPHALIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENLON-PLUS is: 1 to 2 m L (0.5 to 1 mg neostigmine methylsulfate with 0.2 to 0.4 mg glycopyrrolate) IV over 1 minute; may repeat in 10-15 minutes if needed; maximum total dose: 5 m L.. The standard adult dose of ALPHALIN is: 500 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENLON-PLUS and ALPHALIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENLON-PLUS is classified as Category C. First trimester: No adequate studies in pregnant women; animal studies not available. Risk cannot be ruled out. Second/third trimester: Potential fetal toxicity (respiratory depres. ALPHALIN is classified as Category C. First trimester: Increased risk of neural tube defects and cardiovascular malformations; second and third trimesters: Risk of fetal growth restriction and oligohydramnios.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.